OXIDE	
OXIDE Corporation	
Supplementary Explanatory Materials for Fiscal Year 2025 February Financial Results	
April 14, 2025 TSE Growth: 6521	
Illuminate with Innovation - OXIDE	
rright: 2025 OXIDE Corporation. All Rights Reserved.	

I will provide an explanation based on the supplementary explanatory materials for the financial results.

# Agenda

## OXIDE

- 01. FY2025 Feb Consolidated Sesults
- 02. Results by Business Segment [Semiconductor, Healthcare, Frontier Tech.]
- 03. Financial Information
- 04. FY2026 Feb Budget
- 05. Mid-term Management Targets
- 06. Impact of Tariff Policies and Export Controls by the U.S. and China

Copyright: 2025 OXIDE Corporation. All Rights Reserved.

Revenue		Operating	Profit	EBITDA Margin	
JPY 8,39	4M	JPY 12	26M	13.6%	
s FY2024 Feb +J	JPY 1,788M	vs FY2024 Feb	+JPY 1,109M	vs FY2024 Feb	+ 14.8%
Revised budget	+JPY 94M	vs Revised budget	+ JPY 126M		
venue and Operating erating profitability.	Profit both excee	eded the revised budget dis	sclosed in the third qu	arter results, and the Com	pany returne

First of all, I would like to explain the highlights of the Full year financial results for FY2025 Feb.

Revenue and Operating Profit both exceeded the revised budget disclosed in the third quarter results, and the company returned to operating profitability.

Cash generation capability was restored, with an EBITDA margin of 13.6%.

Revenue: JPY 8,394M (up	JPY 94M from the rev	ised budget; up	o JPY 1,788M f	rom the previou	ıs year)		
Operating Profit: JPY 126	5M (up JPY 126M from	the revised bud	dget, up JPY 1,	109M from the	previous year)		
EBITDA: JPY 1,145M (up	JPY 1,222M from the p	revious year)					
						(	(Unit : JPY M, %
	FY24 Feb			FY25 Feb			Variance
Item	Full year	1Q	2Q	3Q	4Q	Full year	
Revenue	6,606	1,388	2,010	2,322	2,673	8,394	1,78
Operating Profit	▲ 983	▲ 406	9	39	482	126	1,10
(Operating Profit Margin)	▲ 14.9%	▲ 29.3%	0.5%	1.7%	18.1%	1.5%	16.4
R&D Expenditure	1,049	315	311	365	304	1,296	24
CAPEX	2,035	-	-	-	-	1,676	▲ 35
EBITDA*1	▲ 77	▲ 144	280	309	699	1,145	1,22
(EBITDA margin∗2)	▲ 1.2%	▲ 10.4%	14.0%	13.3%	26.2%	13.6%	14.8

I would like to explain our Full year results for FY2025 Feb.

01. Consolidated Results

Revenue was JPY 8,394M. This is an increase of JPY 94M over the revised budget and an increase of JPY 1,788M over the previous year.

Operating Profit was JPY 126M. This is an increase of JPY 126M over the revised budget and an increase of JPY 1,109M over the previous year.


EBITDA was JPY 1,145M. This is an increase of JPY 1,222M from the previous year.

Consolidated Ba	alance Sheet		OXIDE
breach of a covenant o	sets are expected to decrease due to impairmen n maintenance of net assets in its financial cove with the same amount of the maturing borrow	enants. The Company has agreed with the bar	
	FY25 Feb Consolida	ted Balance Sheet (Unit : JPY M	)
	Cash and deposits, etc. 2,245 (+614 compared to the end of the previous period)		
	Other current assets 6,278 (+351)		
		Other liabilities 2.423 (▲11)	
	fixed assets 9,681 (▲2011)	net assets 5,412 (▲2.198)	
	Assets	Liabilities and Net Assets	-

I will now explain the consolidated balance sheet.


The Company's net assets are expected to decrease due to impairment of goodwill and other factors, and the Company will be in breach of a covenant on maintenance of net assets in its financial covenants.

However, the Company has obtained the consent of the bank with which it does business to repay its long-term borrowings as originally contracted.




I will explain about consolidated cash flow.

Consolidated operating cash flow for FY2025 Feb has turned positive, and the deficit in investing cash flow has narrowed significantly.




Next, I will explain the composition of Revenue by business segment.

Of the JPY 8,394M in revenue, 56% came from the Semiconductor business, 15% from the Healthcare business, and 29% from the Frontier Tech business.




I will explain our business performance by business segment.

First, Semiconductor revenues reached record highs for both the quarter and Full year. Full year revenue is JPY 4,703M, up JPY 1,563M from the previous year.



The component failure issue in laser products has been completely resolved, and from the fourth quarter, 100% of both new and maintenance products are now equipped with second vendor components.




Revenue trends are explained below.

Revenue for FY2025 Feb increased due to an increase in shipments of existing products resulting from a significant improvement in production efficiency, as well as from contract R&D for new products.

Maintenance demand for the shipped laser products was on the rise in FY2025 Feb, and maintenance revenue increased JPY 308M from the previous year to JPY 782M.

This will lead to the formation of a stable revenue base as a recurring business model.



I will explain New order received and Order backlog in Semiconductor business.


New order received for FY2025 Feb, more than doubled from the previous year to a record high of JPY 5,453M.

As of FY2025 Feb, the Order backlog was JPY 3,211M.



As the most recent topic in Semiconductor business, on April 1, 2025, the Company received the "Award of Excellence" at the 17th Laser Society Industry Awards sponsored by the Laser Society of Japan.


We will contribute to the advancement of next-generation processes in the Semiconductor manufacturing equipment market and aim for further growth.



I would like to explain our Healthcare business.

Revenue from the Healthcare business decreased from the previous year due to a decline in demand from existing customers.


The transaction with a new customer, a top manufacturer of high-performance PET, was delayed due to the time required to finalize delivery specifications, and will be fully implemented from FY2026 Feb.



I would like to explain our Frontier Tech business.

Revenue from the Frontier Tech business reached a record high in the fourth quarter.

Raicol's results were weak due to the prolonged conflict in Israel, but OXIDE's nonconsolidated sales increased by JPY 590M from the previous year on a consolidated basis for the Full year due to contributions from new projects for data centers, etc.



We will explain the research themes of our Frontier Tech business.

In the areas of basic research, Semiconductor testing, and industrial applications, we are the only company in the world to commercialize a 114nm (vacuum ultraviolet) laser, which we sell to research institutes around the world.


Demand for Deep-UV Lasers is growing in the quantum and next-generation semiconductor testing fields, and we received several new development projects.

Inquiries about our deep-ultraviolet single crystals have been increasing rapidly for industrial applications as well as for Semiconductor testing.

For quantum communication applications, a Module for Quantum Entangled Photon Source has been launched and is now being evaluated by research institutions.

In addition to quantum communications and quantum sensing, wavelength conversion devices are beginning to ship for use in the development of quantum computers.

Although the quantum field is still in the research and development stage, our high technology and quality have been recognized, and Revenue has increased to approximately JPY 600M.




In the area of generation AI and data center applications, we have begun sales of Faraday Rotators, which have the property of rotating the direction of polarization of light. Demand for Faraday Rotators is increasing against the backdrop of growing global demand for data centers.

In space applications, our high-performance scintillator single crystals have been adopted for radiation detection applications in space due to their high temperature stability and superior  $\gamma$ -ray energy capability.

In the area of solution-method SiC, we have formed a business alliance with JS Foundry, to establish a value chain for solution-method SiC processing and epitaxy.

We have succeeded in growing inclusion-free, high-quality, large SiC single crystals and have started sample shipments.

Based on these achievements, the Company aims to enter the growing market and create new value.




Next, I will explain CAPEX.

CAPEX totaled JPY 1,676M, a decrease from the peak in FY2024 Feb, when major CAPEX over the past several years peaked.

Through major investments to date, we have expanded our manufacturing capacity, particularly in the Semiconductor business.

We are shifting from a phase of large-scale capital investment to a phase of business growth and profitability improvement.



I would like to explain R&D Expenditure.

R&D Expenditure amounted to JPY 1,296M, or about 15% of Revenue.

R&D Expenditure increased from the previous year, mainly focusing on the Semiconductor business, power semiconductor materials, and the quantum field.

Research and development is essential for future growth and we will continue to invest in this area.

### 04. budget for the FY2026 Feb FY2026 Feb budget (consolidated)

## OXIDE

Revenue: JPY 8,713M (up JPY 319M from the previous year).

• Operating Profit Margin: JPY 409M (up JPY 283M from the previous year), Operating Profit Margin: 4.7%.

■ ■ EBITDA JPY 1,278M (up JPY 133M from the previous year), EBITDA margin 14.7%.


Item	FY25 Feb	FY26 Feb					
Item	Full year	1Q	2Q	3Q	4Q Ful	Full year	variance
Revenue	8,394	1,814	2,162	2,091	2,645	8,713	31
Semiconductor	4,703	890	1,068	1,061	1,534	4,555	<b>▲</b> 14
Healthcare	1,226	401	584	534	649	2,170	944
Frontier Tech	2,464	521	509	495	461	1,987	<b>▲</b> 47'
Operating Profit	126	▲ 215	265	32	326	409	28
(Operating Profit Margin)	1.5%	(11.9%)	12.3%	1.5%	12.4%	4.7%	3.2%
R&D Expenditure	1,296	337	282	306	403	1,330	3
EBITDA <sub>*1</sub>	1,145	6	479	246	545	1,278	13
(EBITDA margin <sub>*2</sub> )	13.6%	0.4%	22.2%	11.8	20.6%	14.7%	1.09

We would like to present our consolidated budget for FY2026 Feb.

Revenue is expected to increase by JPY 319 M from the previous year to JPY 8,713M for the Full year

Operating Profit is expected to increase by JPY 283M from the previous year to JPY 409M. Operating Profit Margin is 4.7%.

EBITDA is expected to increase by JPY 133M from the previous year to JPY 1,278M, with an EBITDA margin of 14.7%.



I would like to explain our Mid-term management targets.

The management indicator targets for FY2029 Feb are Revenue of JPY 13 billion, Operating Profit Margin of 12%, and EBITDA Margin of 22%.

In addition to the growth of existing businesses, we aim to generate business revenue in the quantum field as a new business pillar.


	5 ,	the impact of tariff policies and export cor ake proactive action in response to busine	,	
	Semiconductor Healthcare		Frontier Tech	
ur production sites	Japan	Japan	Japan and Israel	
U.S. Policy Effects	[Risk] We believe that the impact of the U.S. tariff policy will be limited due to our low dependence on U.S. shipments of laser products. The market share of wavelength conversion single crystals is over 95%, and we believe that replacement with other companies' products will be difficult in terms of quality and production system, and that the impact of the U.S. tariff policy will be limited. [Business Opportunity] U.S. export controls may limit purchases of U.S. products by Chinese Semiconductor equipment manufacturers. Therefore, inquiries to our company are increasing.	[Risk] The degree of impact of the U.S. tariff policy is currently under scrutiny. [Business Opportunity] Even if not affected by Chinese export controls, U.S. crystal manufacturers may see their business development affected by the U.S. tariff policy. Therefore, inquiries to our company may increase.	<ul> <li>[Risk]</li> <li>We believe that the impact of the U.S. tariff polici will be limited due to the low dependence on U.S. shipments of Frontier Tech business products.</li> <li>The impact of the U.S. tariff policy on Raicol's products is expected to be limited, as tariffs on Israeli products are lower than those in other ma countries.</li> <li>[Business Opportunity]</li> <li>U.S. customers may be reluctant to purchase Chinese products due to the U.S. tariff policy and Iong-term procurement concerns. As a result, the number of inquiries to us and Raicol may increase</li> </ul>	
China Policy Effects	[Business Opportunity] China's tariff policy may affect Chinese Semiconductor equipment manufacturers when they purchase products from the United States. Therefore, inquiries to our company are increasing.	[Risk] We are currently examining the degree of impact of China's export controls. [Business Opportunity] China's export controls may limit the purchase of Chinese raw materials by U.S. crystal manufacturers. This may lead to an increase in inquiries to our company.	[Business Opportunities] Prices of laser products, which are not affected b U.S. export controls, may rise due to China's tariff policy. For this reason, inquiries to our company are increasing.	


Finally, we summarize our current views on the impact of tariff policies and export controls in the U.S. and China on our company.

We will continue to monitor regulatory trends and take proactive action in response to business opportunities.

# **OXIDE**

Copyright: 2025 OXIDE Corporation. All Rights Reserved.







### DISCLAIMER

This material was not prepared for the purpose of soliciting investments in securities issued by the Company. The information contained in this material is based on our assumptions and beliefs at the time of preparation and we do not guarantee or promise the accuracy or completeness of

such information.

The report contains risks, economic trends, industry demand, and other uncertainties that may affect actual results. Our estimates and actual results may differ. Please be aware that actual results may differ from our projections.

Amounts in this document are rounded down to the indicated unit, and percentages are rounded off to the indicated unit, so the total of the breakdown may not equal the total. In the fourth quarter of FY2024 Feb, the allocation of the acquisition cost was revised due to the finalization of the PPA for the acquisition of Raicol as a subsidiary. As a result, the figures for the second and third quarters of FY2024 Feb, have been retroactively adjusted.

Illuminate with Innovation - OXIDE

Copyright: 2025 OXIDE Corporation. All Rights Reserved.

https://www.opt-oxide.com

# **Illuminate with Innovation**

The 21st century is often referred to as the era of optics, a time when advancements in optical technologies are transforming industries and shaping the future.

At OXIDE, we are committed to exploring the full potential of optical technology and delivering its benefits to society as swiftly and extensively as possible.

This commitment has been at the core of OXIDE's mission since its founding.

OXIDE